Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Outremont, Canada Clinical Trials

A listing of Outremont, Canada clinical trials actively recruiting patients volunteers.

RESULTS

Found (18) clinical trials

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

The study includes a 52-week, randomized, double-blind, placebo-controlled period, followed by a 2-week follow- up. Approximately 125 boys with DMD will be enrolled in this trial, with 2 boys receiving edasalonexent for every 1 boy receiving placebo. Following completion of the treatment period, patients may elect to continue in a ...

Phase

1.18 miles

Learn More »

Hormone Therapy in Treating Men With Stage IV Prostate Cancer

OBJECTIVES: Primary - Compare the survival of patients with metastatic stage IV prostate cancer responsive to combined androgen-deprivation therapy (CAD) treated with intermittent vs continuous CAD. - Compare the effects of these treatment regimens on impotence, libido, and vitality/fatigue as well as the physical and emotional well-being of these patients. ...

Phase

1.48 miles

Learn More »

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

In North America, the number of new cases of prostate cancer increases every year. To this day, the standard curative treatment for high risk prostate cancer patients is external beam radiation therapy (EBRT) combined with hormonal manipulation (Luteinizing hormone-releasing hormone LHRH agonists such as Eligard) to lower levels of testosterone ...

Phase

1.51 miles

Learn More »

Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy

The efficacy of Rapaflo treatment will be assessed using the International Prostate Symptom Score (IPSS). The IPSS will be assessed at baseline before RT, 4 weeks into RT, the last day of RT, and monthly thereafter for a total duration of 6 months from start of RT. Patients will have ...

Phase

1.51 miles

Learn More »

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Patients with PSMA positive scans will be randomized in a 2:1 ratio to receive either 177Lu-PSMA-617 plus best supportive/best standard of care or to receive best supportive/best standard of care only. Best supportive/best standard of care will be determined by the treating physician/investigator but will exclude investigational agents, cytotoxic chemotherapy, ...

Phase

1.51 miles

Learn More »

Efficacy and Safety of AAV2-REP1 for the Treatment of Choroideremia

This is a phase 3 clinical trial of a gene therapy vector made from adeno-associated virus (AAV) called AAV2-REP1 for the treatment of Choroideremia. Participating subjects will be required to attend a screening visit during which their suitability for the study will be assessed, and eligible subjects will be randomized ...

Phase

1.67 miles

Learn More »

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

PRIMARY OBJECTIVES: I. To determine whether stereotactic body radiation therapy (SBRT) can be shown to be superior to hypofractionated intensity-modulated radiation therapy (IMRT) in terms of genitourinary (GU) and gastrointestinal (GI) toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel Health Related ...

Phase

1.88 miles

Learn More »

The Metformin Active Surveillance Trial (MAST) Study

This study aims to see if metformin can delay the time to progression in men with low risk prostate cancer when compared to a placebo.

Phase

2.2 miles

Learn More »

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

Phase

2.2 miles

Learn More »

This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to ...

Phase

2.32 miles

Learn More »